Revisiting Circulating Extracellular Matrix Fragments as Disease Markers in Myelofibrosis and Related Neoplasms
Philadelphia chromosome-negative chronic myeloproliferative neoplasms (MPNs) arise due to acquired somatic driver mutations in stem cells and develop over 10-30 years from the earliest cancer stages (essential thrombocythemia, polycythemia vera) towards the advanced myelofibrosis stage with bone marrow failure. The JAK2V617F mutation is the most prevalent driver mutation. Chronic inflammation is considered to be a major pathogenetic player, both as a trigger of MPN development and as a driver of disease progression. Chronic inflammation in MPNs is characterized by persistent connective tissue remodeling, which leads to organ dysfunction and ultimately, organ failure, due to excessive accumulation of extracellular matrix (ECM). Considering that MPNs are acquired clonal stem cell diseases developing in an inflammatory microenvironment in which the hematopoietic cell populations are progressively replaced by stromal proliferation-"a wound that never heals"-we herein aim to provide a comprehensive review of previous promising research in the field of circulating ECM fragments in the diagnosis, treatment and monitoring of MPNs. We address the rationales and highlight new perspectives for the use of circulating ECM protein fragments as biologically plausible, noninvasive disease markers in the management of MPNs.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:15 |
|---|---|
| Enthalten in: |
Cancers - 15(2023), 17 vom: 29. Aug. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Hasselbalch, Hans Carl [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Revised 11.09.2023 published: Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.3390/cancers15174323 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM361840985 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM361840985 | ||
| 003 | DE-627 | ||
| 005 | 20231226090010.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/cancers15174323 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1206.xml |
| 035 | |a (DE-627)NLM361840985 | ||
| 035 | |a (NLM)37686599 | ||
| 035 | |a (PII)4323 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Hasselbalch, Hans Carl |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Revisiting Circulating Extracellular Matrix Fragments as Disease Markers in Myelofibrosis and Related Neoplasms |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 11.09.2023 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a Philadelphia chromosome-negative chronic myeloproliferative neoplasms (MPNs) arise due to acquired somatic driver mutations in stem cells and develop over 10-30 years from the earliest cancer stages (essential thrombocythemia, polycythemia vera) towards the advanced myelofibrosis stage with bone marrow failure. The JAK2V617F mutation is the most prevalent driver mutation. Chronic inflammation is considered to be a major pathogenetic player, both as a trigger of MPN development and as a driver of disease progression. Chronic inflammation in MPNs is characterized by persistent connective tissue remodeling, which leads to organ dysfunction and ultimately, organ failure, due to excessive accumulation of extracellular matrix (ECM). Considering that MPNs are acquired clonal stem cell diseases developing in an inflammatory microenvironment in which the hematopoietic cell populations are progressively replaced by stromal proliferation-"a wound that never heals"-we herein aim to provide a comprehensive review of previous promising research in the field of circulating ECM fragments in the diagnosis, treatment and monitoring of MPNs. We address the rationales and highlight new perspectives for the use of circulating ECM protein fragments as biologically plausible, noninvasive disease markers in the management of MPNs | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a MPN | |
| 650 | 4 | |a MPNs | |
| 650 | 4 | |a circulating extracellular matrix (ECM) proteins | |
| 650 | 4 | |a hyaluronan | |
| 650 | 4 | |a laminin | |
| 650 | 4 | |a myeloproliferative neoplasms | |
| 650 | 4 | |a neoepitopes | |
| 650 | 4 | |a procollagen type I C-terminal propeptide (PICP) | |
| 650 | 4 | |a protein fingerprints | |
| 650 | 4 | |a serum procollagen III N-terminal propeptide (PIIINP) | |
| 650 | 4 | |a type IV collagen | |
| 700 | 1 | |a Junker, Peter |e verfasserin |4 aut | |
| 700 | 1 | |a Skov, Vibe |e verfasserin |4 aut | |
| 700 | 1 | |a Kjær, Lasse |e verfasserin |4 aut | |
| 700 | 1 | |a Knudsen, Trine A |e verfasserin |4 aut | |
| 700 | 1 | |a Larsen, Morten Kranker |e verfasserin |4 aut | |
| 700 | 1 | |a Holmström, Morten Orebo |e verfasserin |4 aut | |
| 700 | 1 | |a Andersen, Mads Hald |e verfasserin |4 aut | |
| 700 | 1 | |a Jensen, Christina |e verfasserin |4 aut | |
| 700 | 1 | |a Karsdal, Morten A |e verfasserin |4 aut | |
| 700 | 1 | |a Willumsen, Nicholas |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cancers |d 2009 |g 15(2023), 17 vom: 29. Aug. |w (DE-627)NLM198667213 |x 2072-6694 |7 nnns |
| 773 | 1 | 8 | |g volume:15 |g year:2023 |g number:17 |g day:29 |g month:08 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3390/cancers15174323 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 15 |j 2023 |e 17 |b 29 |c 08 | ||